Back to catalogue
№ 222 32 filings · 2021-10-07 → 2026-07-22

HARDIDE PLC

HDD
Chemicals Share price 107p Market cap £84m Overall fit 420 /1000

Genuine operating leverage and improving cashflow fit the investor mandate well, but the AI-beneficiary angle is thin (semiconductors mentioned as a pipeline sector only) and the ~12x share price move has removed the valuation cushion — right business model, no longer at an obvious price.

Fair value range 70p–105p Mid case · £69m
Absolute upside -18.2% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean quantified guidance with explicit prior-expectations references
  • Verifiable operating-leverage math from reported P&L
  • Multiple consecutive positive revisions in FY26 support the trajectory
Limits the call
  • Terminal value depends on 'double again' plan with high customer concentration
  • Valuation is heavily multiple-dependent after a ~12x share-price re-rating
Methodology

Forward EV/EBITDA with DCF cross-check

In one line · bull case

Small-cap specialty coatings business delivering explosive operating leverage as a well-invested asset base is finally utilised, with cash generation now flywheel-positive.

In one line · biggest risk

Customer concentration in a fast-ramp North American energy contract combined with a ~12x share-price re-rating leaves valuation exposed to any execution slip.

Drivers
AI beneficiary 30 /100
Semiconductor sector flagged as new pipeline but not yet a revenue line; predominantly energy/aerospace/industrial exposure today.
Operating leverage 82 /100
Fixed cost base with 57% gross margin, £5m cash breakeven and stated capacity to £10-12m without major capex — textbook high leverage.
Earnings vs expectations 78 /100
Three consecutive upward FY26 revisions and prior FY24/25 in-line-to-beat pattern under new CEO.
Growth momentum 85 /100
Revenue running at 100%+ YoY in Q3 FY26 with guidance sequentially raised and 'double again' target set.
Moat 55 /100
Patented CVD technology, NADCAP Gold aerospace accreditations and long qualification cycles create switching costs, but scale is small.
Earnings quality 68 /100
Reported EBITDA converts reasonably to cash; capex has run below D&A; some working-capital swings tied to project timing.
Management quality 65 /100
New CEO Hamblin has delivered rapid turnaround since 2024; capital allocation improving after prior dilutive raises.
Cyclicality 60 /100
Meaningful cyclicality via oil & gas and aerospace customers, tempered by growing industrial/aerospace recurring work.
Leverage 30 /100
Net debt £1.6m including leases at FY25, well within EBITDA multiples; self-funding capex programme announced.

Hardide plc (AIM: HDD) — Investment Research Note

Executive summary

Hardide is a UK/US small-cap specialty coatings business that applies patented CVD tungsten carbide/metal matrix coatings to engineering components (energy, aerospace, industrial). After a decade of losses and restructuring, the business is delivering exceptional operating leverage — Q3 FY26 trading update 2026-07-22 confirmed YTD revenues of £8.9m already exceed all of FY25's £6.0m, with FY26 EBITDA now expected "materially ahead" of £4.3m guidance. The most important valuation fact is that the share price has re-rated ~12× from ~7p to 87.5p in twelve months, so the business is now being priced for the "double again in 2-3 years" growth path.

Fair value estimate

  • Fair value range: 70p – 105p per share (implied market cap £55m – £83m).
  • Methodology: Forward EV/EBITDA blended with a DCF sanity check. FY26E EBITDA ~£5.0m (assuming "materially ahead" of £4.3m guidance 2026-07-22) at 12-18× EV/EBITDA gives EV £60-90m, less £2m net debt (extrapolating FY25's £1.6m 2026-01-22) → equity £58-88m. FY28 walk: if the "double again" plan lands (£25m revenue), 25% EBITDA margin from operating leverage → £6m+ EBITDA, discounted back at 12% supports the upper band.
  • Current market cap: £69.0m at 87.5p sits mid-range.
  • Absolute upside/downside vs midpoint (~87p): roughly flat (~0%). This is a fairly-priced growth stock, not a bargain.

Sector context

  • Confirmed sector: Basic Materials / Chemicals (specialty industrial coatings).
  • Quality/growth/leverage profile vs peers: Growth well above sector median; balance sheet acceptable (small net debt, no equity dilution planned); quality below larger peers due to small scale and customer concentration.
  • Listed peers: no direct pure-play UK-listed CVD coating specialist. The closest reference points are Bodycote (BOY.L, thermal processing/coatings, much larger and cyclical), Coats Group (COA.L, specialty industrial) and international names like Praxair Surface Technologies (Linde) and Oerlikon Balzers.

Investment thesis

  1. Rapid revenue and margin inflection with material contract wins driving conviction: Revenue tracking to at least £13-14m in FY26 vs £6m FY25 2026-04-28, 2026-07-22, driven by (i) a major North American energy customer (£1.75m Q1 order plus £1.8m April top-up), (ii) Airbus cargo-door 10-year contract worth £6-8m 2025-01-29, and (iii) new sectors including a nascent semiconductor pipeline explicitly flagged in the July trading update 2026-07-22.
  2. Powerful operating leverage on a well-invested asset base: EBITDA margin ran from -8% (FY23) → 0% (FY24) → 17% (FY25) → ~20%+ H1 FY26 2026-03-24. Existing capacity supports £10-12m at single shift, and £4.5m of new-reactor capex takes theoretical capacity meaningfully higher 2026-07-22. Management explicitly cites "high operational gearing".
  3. Cash-generative and self-funding after years of losses: Cash rose from £0.7m (FY24) → £0.8m (FY25) → £1.2m (Dec 2025), net debt down to £1.6m, and management believes no equity raise is needed 2026-01-22. £4.5m capex programme funded from cash and borrowings, not shareholders — a structural change from the dilutive 2022 and 2024 raises.

Key risks

  1. Customer concentration in an emerging growth phase: Top six customers account for the majority of sales 2026-01-22; the North American energy customer alone accounts for a large share of the FY26 uplift. One major contract loss or delay would materially dent forecasts.
  2. Tungsten gas input cost volatility and geopolitical exposure: Explicitly flagged — costs stabilised but "at higher levels", exacerbated by defence-driven demand and China export restrictions 2026-07-22. Only ~50% of FY27 tungsten needs secured. Recovery via price surcharges is not guaranteed and depends on customer acceptance.
  3. Valuation risk after a ~12× share-price move: The stock has priced in most of the "double again" scenario already (52-week range 6.5p → 107p; monthly closes went from 7.4p in Sept 2025 to 87.5p today). Any delay in the North American customer's ramp, Middle East development slippage, or a soft aerospace print could produce a sharp de-rating not disclosed but inferred from filings.

Operating leverage

Hardide is a textbook high-fixed-cost specialty industrial. Revenue passed the ~£5m cash breakeven 2024-01-29 and each incremental pound is now dropping through at a very high rate. The delivered evidence:

  • FY25: revenue +27% (£4.7m→£6.0m) drove EBITDA from ~breakeven to £1.0m — incremental EBITDA/revenue ≈ 80%.
  • H1 FY26: revenue +60% (£2.8m→£4.5m) drove EBITDA from £0.4m to £1.3m — incremental EBITDA/revenue ≈ 55% 2026-03-24.
  • Gross margin trajectory: 48%→57% (FY24→FY25) 2026-01-22.

Gross margins already sit at ~57%. Central overhead is largely flat. Existing single-shift capacity is stated at £10-12m annualised revenue 2026-01-22; a 10-20% beat above current expectations (roughly £14-16m vs £13.4m plan) would likely push EBITDA meaningfully above £5m — margin at scale plausibly 30%+, meaning an incremental £2m of revenue at these levels could add £1m of EBITDA. The new £4.5m reactor programme (three units, live in late FY27) extends this profile. This is exactly the operating-leverage profile the investor mandate seeks.

Value-trap signals

None identified. To the contrary — revenue is growing, guidance is being raised, cash is building, and the balance sheet is improving. The historic pre-2024 track record of losses and dilutive raises is a caveat on management history but no longer a current-state warning.

Earnings vs. expectations

The recent track record is a series of upgrades and beats:

  • FY24 (Jan 2025): Management guided in Feb 2024 to "broadly in line" full-year revenue after a slow H1; ultimately delivered £4.7m with H2 much stronger and £0.5m H2 adjusted EBITDA — a positive surprise vs the depressed Feb 2024 guidance.
  • FY25 (Jan 2026): Guidance in Oct 2025 for ~£6.0m revenue and £1.0m EBITDA at 16% margin was hit precisely — in-line print.
  • FY26 (year to date): Sequential upgrades — Mar 2026 trading update lifted H1 expectations to £4.5m revenue 2026-03-24; April 2026 flagged "materially ahead" 2026-04-28; July trading update lifted again to "materially ahead" of the £13.4m/£4.3m base 2026-07-22.

Pattern: three consecutive positive revisions during FY26, no misses since new CEO Matt Hamblin took over in mid-2024.

Conviction

Rating: 3 (moderate).

Anchors: (i) disclosure is clean for an AIM small-cap with quantified guidance and explicit "previous expectations" callouts, making triangulation possible; (ii) the operating-leverage math is verifiable from the reported income statements; (iii) FY26 trajectory is well-signposted by the July update.

Limits: (i) the fair-value range is wide because the terminal earnings power depends heavily on execution against a "double again" plan whose customer concentration is high; (ii) I cannot cross-check against sell-side consensus in the filings, only against the company's own numbered guidance references; (iii) the enormous share-price re-rating (7p→87.5p) means valuation is heavily dependent on the growth multiple applied.

Filings consulted · 33

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-22Trading Update2026-07-22_9680650_trading-update.md0.85
  2. 2026-04-28New Order Intake And Notice OF Interim Results2026-04-28_9540467_new-order-intake-and-notice-of-interim-results.md0.90
  3. 2026-03-24Result OF Agm2026-03-24_9490006_result-of-agm.md0.30
  4. 2026-03-24Agm Trading Statement2026-03-24_9487953_agm-trading-statement.md0.85
  5. 2026-03-17Notice OF Agm2026-03-17_9477020_notice-of-agm.md0.30
  6. 2026-01-22Annual Results TO 30 September 20252026-01-22_9374491_annual-results-to-30-september-2025.md0.85
  7. 2025-10-22Year End Trading Update2025-10-22_9185811_year-end-trading-update.md0.72
  8. 2025-03-18Result OF Agm2025-03-18_8785390_result-of-agm.md0.20
  9. 2025-03-18Agm Trading Statement2025-03-18_8783434_agm-trading-statement.md0.55
  10. 2025-01-29Annual Results For Year Ended 30 September 20242025-01-29_8710449_annual-results-for-year-ended-30-september-2024.md0.65
  11. 2024-10-21Year End Trading Update2024-10-21_8497244_year-end-trading-update.md0.55
  12. 2024-03-25Result OF Agm2024-03-25_8105476_result-of-agm.md0.14
  13. 2024-03-25Agm Statement2024-03-25_8103591_agm-statement.md0.18
  14. 2024-02-21Result OF Fundraising2024-02-21_8049748_result-of-fundraising.md0.32
  15. 2024-02-21Proposed Equity Fundraising2024-02-21_8049640_proposed-equity-fundraising.md0.32
  16. 2024-02-21Audited Annual Report And Notice OF Agm2024-02-21_8049620_audited-annual-report-and-notice-of-agm.md0.43
  17. 2024-02-08Preliminary Fy23 Results Amp Fy24 Trading Update2024-02-08_8027580_preliminary-fy23-results-amp-fy24-trading-update.md0.38
  18. 2023-10-18Year End Trading Update2023-10-18_7822901_year-end-trading-update.md0.38
  19. 2023-05-17Interim Results2023-05-17_7529972_interim-results.md0.23
  20. 2023-03-23Result OF Agm2023-03-23_7279742_result-of-agm.md0.07
  21. 2023-03-23Agm Statement2023-03-23_7278281_agm-statement.md0.10
  22. 2023-02-22Posting OF Annual Report And Notice OF Agm2023-02-22_7504749_posting-of-annual-report-and-notice-of-agm.md0.24
  23. 2023-02-08Annual Results For Year Ended 30 September 20222023-02-08_7401990_annual-results-for-year-ended-30-september-2022.md0.25
  24. 2022-12-22Funding And Annual Results Update2022-12-22_7224176_funding-and-annual-results-update.md0.25
  25. 2022-10-13Year End Trading Update2022-10-13_7303476_year-end-trading-update.md0.21
  26. 2022-09-09Result OF Fundraising2022-09-09_7272929_result-of-fundraising.md0.17
  27. 2022-09-09Proposed Equity Fundraising2022-09-09_7271690_proposed-equity-fundraising.md0.17
  28. 2022-07-14Trading Update2022-07-14_6994863_trading-update.md0.21
  29. 2022-05-10Interim Results2022-05-10_7240775_interim-results.md0.23
  30. 2022-03-11Result OF Agm2022-03-11_6896062_result-of-agm.md0.07
  31. 2022-03-11Agm Statement2022-03-11_6894721_agm-statement.md0.10
  32. 2022-02-15Posting OF Annual Report And Notice OF Agm2022-02-15_6849307_posting-of-annual-report-and-notice-of-agm.md0.24
  33. 2021-10-07Year End Trading Update2021-10-07_6713093_year-end-trading-update.md0.21

This research note was authored by a large language model after reading 32 regulatory filings published between 2021-10-07 and 2026-07-22. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.